Table 1 Summary of clinical studies addressing the outcome of patients with steroid-refractory GvHD treated with MSCs

From: Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases

				outcome (total)			outcome (%)
study	# of patients (children/adults)	mean age (years)	sex (m/f)	CR	PR	NR	CR	PR	NR	reference
1	19 adults	27.5	14/5	4	10	5	21.1	52.6	26.3	Weng JY 2010
2	7 children	14	ns	3	1	3	42.9	14.3	42.9	Muller I 2008
3	55 (25 children, 30 adults)	22	34/21	30	9	16	54.5	16.4	29.1	Le Blanc K 2008
4	12 adults	ns	ns	3	6	3	25.0	50.0	25.0	Zhang LS 2009
5	13 adults	58	7/6	1	1	11	7.7	7.7	84.6	von Bonin M 2009
6	2 children, 6 adults	43.25	7/1	6	0	2	75.0	0.0	25.0	Ringdén O 2006
7	31 adults	52	21/10	24	5	2	77.4	16.1	6.5	Kebriaei P 2009
8	6 adults	40	2/4	5	0	1	83.3	0.0	16.7	Fang B 2007
9	12 children	7	10/2	7	5	0	58.0	42.0	0.0	Prasad VK 2010
10	2 adults	32	1/1	0	2	0	0.0	100	0.0	Lim JH 2010
11	3 adults	48	1/2	0	1	2	0	33.3	66.7	Arima N 2010
12	11 children	9	8/3	3	5	3	27.3	45.4	27.3	Lucchini G 2010
13	2 children	13.5	1/1	2	0	0	100	0	0	Fang B 2007
14	2 children	11.5	1/1	2	0	0	100	0	0	present study
	mean age range	27.0 0.5-67	65.2/34.8%

Apart from the present study only those studies were included that reported on at least 2 individuals and that were available at MEDLINE^® (NCBI) until June 2011. CR = complete response; PR = partial response; NR = no response; ns = not specified. Children was defined as age < 18 years.

Back to article page